Sign In
Buy GNPX
$0.720
-0.0153 (-2.08%)
At Close: Jun 03, 2026
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
08:31am, Tuesday, 02'nd Apr 2024
NPRL2 Gene Therapy Induces Anti-Tumor Activity in Anti-PD1 Resistant KRAS/STK11 Mutant Non-Small Cell Lung Cancer in a Humanized Mouse Model Provides Additional Preclinical Validation of Oncoprex® De
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
04:10pm, Friday, 22'nd Mar 2024
AUSTIN, Texas , March 22, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for pati
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
01:24pm, Tuesday, 19'th Mar 2024
AUSTIN, Texas , March 19, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for pati
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
08:36am, Tuesday, 19'th Mar 2024
AUSTIN, Texas , March 19, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for pati
Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors applicable to Genprex's Acclaim-2 and Acclaim-3 clinical trials AUSTIN, Texas , M
Reqorsa® Immunogene Therapy May be a Potential Therapy for ALK-Positive Lung Cancer REQORSA has Anti-Tumor Mechanisms that Target and Disrupt the Metabolism of Cancer Cells NPRL2 Gene Therapy Induces
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
08:15am, Wednesday, 07'th Feb 2024
Reqorsa® Therapy May Be Potential Treatment for ALK-Positive Lung Cancer Three Collaborators Selected to Present Positive Nonclinical Data on Genprex Oncology Program at the 2024 American Associatio
Genprex to Present at Upcoming BIO CEO & Investor Conference
07:30am, Tuesday, 06'th Feb 2024
Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Feb. 6, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene
Expects to Complete Enrollment of Phase 2a Expansion Study by the end of 2024 Acclaim-1 Study Has FDA Fast Track Designation AUSTIN, Texas , Feb. 5, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or t
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024
08:42am, Wednesday, 31'st Jan 2024
AUSTIN, Texas , Jan. 31, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patient
Genprex Provides Business Update and Outlook for 2024
07:00am, Friday, 05'th Jan 2024
Acclaim-1 Phase 2a and Acclaim-3 Phase 1 clinical studies opening for enrollment in January 2024 Poised for FDA guidance regarding diabetes gene therapy program in 2024 AUSTIN, Texas , Jan. 5, 2024 /P
Genprex to Present at BIO-Europe 2023 Conference
07:30am, Wednesday, 01'st Nov 2023
Presentation to be held on Tuesday, November 7, 2023 from 4:45 – 5:00 p.m. UTC AUSTIN, Texas , Nov. 1, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-sta
Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"
07:30am, Friday, 20'th Oct 2023
Webinar to be held on Friday, October 27, 2023 from 12:30 pm - 1:45 pm Eastern Time AUSTIN, Texas , Oct. 20, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical
Acclaim-1 Phase 1 study had no Dose Limiting Toxicity, and results establish Phase 2 Recommended Dose as well as provide data showing efficacy of REQORSA® in combination with Tagrisso® Preclinical r
GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know
01:32pm, Monday, 04'th Sep 2023
GENPREX (GNPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
